Preview

Научно-практическая ревматология

Расширенный поиск

ИММУНОЛОГИЧЕСКИЕ МАРКЕРЫ АНТИФОСФОЛИПИДНОГО СИНДРОМА. ЧАСТЬ II - МАРКЕРЫ ПОВРЕЖДЕНИЯ ЭНДОТЕЛИЯ, ВОСПАЛЕНИЯ И АКТИВАЦИИ КЛЕТОЧНОГО ИММУНИТЕТА

https://doi.org/10.14412/1995-4484-2010-733

Полный текст:

Список литературы

1. <div><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004; 440 с.</p><p>Shoenfeld Y., Meroni P.L., Cervera R. Antiphospholipid syndrome dilemmas still be to solved: 2008 status. Ann Rheum Dis 2008; 67: 438-42.</p><p>Raschi E., Testoni C., Borghi M.O. et al. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother 2003; 57: 282-6.</p><p>Del Papa N., Guidali L., Sala A. et al. Endothelial cells as target for antiphospholipid antibodies: human polyclonal and monoclonal anti-beta2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta2-glycoprotein I and induce endothelial activation. Arthr Rheum 1997; 40: 551-61.</p><p>Pierangeli S.S., Liu X., Espinola R. et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 388-95.</p><p>Espinola R.G., Liu X., Colden-Stanfield M. et al. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002; 1: 843-8.</p><p>Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245-50.</p><p>Tailor A.N., Granger D.G. Role of adhesion molecules in vascular regulation and damage. Curr Hypertens Reports 2000; 2: 78-83.</p><p>Guering A.J.H. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.</p><p>Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J.H. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.</p><p>Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999; 616 с.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и др. Растворимые молекулы адгезии при антифосфолипидном синдроме, связанном с системной красной волчанкой, и первичном антифосфолипиддном синдроме. Тер. aрх. 2002; 5: 23-7.</p><p>Kaplanski G., Cacoub P., Farnarier C. et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus- related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthr Rheum 2000; 43: 55-64.</p><p>Spronk P.E., Bootsma H., Huitema M.G. et al. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97: 439-44.</p><p>Joseph J.E., Donohoe S., Harrison P. et al. Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus 1998; 7: 333-40.</p><p>Williams F.M., Parmar K., Hughes G.R., Hunt B.J. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84: 742-6.</p><p>Takeda I., Kaise S., Nishimaki T., Kasukawa R. Soluble P-selectin in the plasma of patients with connective tissue diseases. Int Arch Allergy Appl Immunol 1994; 105: 128-34.</p><p>Mannucci P.M. von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-62.</p><p>Lai K.N., Leung J.C., Lai K.B. et al. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 81: 229-38.</p><p>Новиков А.А., Александрова Е.Н., Попкова Т.В. и др. Антиген фактора Виллебранда при системной красной волчанке и антифосфолипидном синдроме. Науч.-практич. ревматол. 2004; 4: 35-8.</p><p>Pepys M.B., Lanham J.G., De Beer F.C. C-reactive protein in SLE. Clin Rheum Dis 1982; 8: 91-103.</p><p>Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.</p><p>Du Clos T.W. C-reactive protein as a regulator of autoimmunity and inflammation. Arthr Rheum 2003; 48: 1475-7.</p><p>Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.</p><p>Насонов Е.Л., Панюгова Е.В., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-62.</p><p>Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.</p><p>Venugopal S.K., Devaraj S., Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-7.</p><p>Ильина А.Е., Клюквина Н.Г., Александрова Е.Н. и др. Атеросклеротическое поражение сосудов при системной красной волчанке у мужчин: связь с концентрацией С-реактивного белка. Тер. aрх. 2005; 6: 61-5.</p><p>Barnes E.V., Narain S., Naranjo A. et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576-82.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и др. Клинико-иммунологическая оценка высокочувствительного метода определения С-реактивного белка при антифосфолипидном синдроме. Науч.-практич. ревматол. 2007; 1: 9-15.</p><p>Клюквина Н.Г., Баранов А.А., Александрова Е.Н., Насонов Е.Л. С-реактивный белок при системной красной волчанке у мужчин: связь с тромботическими осложнениями. Клин. мед. 1997; 8: 24-7.</p><p>Szalai A.J., Alarcon G.S., Calvo-Alen J. et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005; 44: 864-8.</p><p>Shoenfeld Y., Blank M., Cervera R. et al. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006; 65: 2-6.</p><p>Visvanathan S., McNeil H.P. Cellular immunity to 2-glycoprotein I in patients with antiphospholipid syndrome. J Immunol 1999; 162: 6919-25.</p><p>Karakantza M., Theodorou G.L., Meimaris N. et al. Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome. Ann Hematol 2004; 83: 704-11.</p><p>Ярилин А.А. Система цитокинов и принципы ее функционирования в норме и патологии. Иммунология 1997; 5: 7-14.</p><p>Hamid C., Norgate K., D'Cruz D.P. Anti-β2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007; 66: 1000-7.</p><p>Girardi G., Berman J., Redecha P. et al. Complement C5a receptors and neutrophil mediated fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54.</p><p>Raines E.W., Ferri N. Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. Lipid Res 2005; 46: 1081-92.</p><p>Frampton G., Hicks J., Cameron J.S. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 1991; 39: 1225-31.</p><p>Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.</p><p>Asanuma Yu., Chung C.P., Oeser A. et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539-45.</p><p>Dayer E., Dayer J.-M., Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheum 2007; 3: 512-20.</p><p>Spronk P.E., ter Borg E.J., Limburg P.C., Kallenberg C.G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 1992; 90: 106-10.</p><p>Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.</p><p>Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.</p><p>Kitani A., Hara M., Hirose T. et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992; 88: 75-83.</p><p>Brink I., Thiele B., Burmester G.R. Effects of anti-CD4 antibodies on the release of IL-6 and TNF alpha in whole blood samples from patients with systemic lupus erythematosus. Lupus 1999; 8: 723-30.</p><p>Neng Lai K., Leung J.C., Bik Lai K. et al. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J Pathol 1996; 178: 451-7.</p><p>Александрова Е.Н., Новиков А.А., Решетняк Т.М. и др. Цитокины и неоптерин при антифосфолипидном синдроме. Науч.-практич. ревматол. 2009; 2: 10-16.</p><p>Forastiero R.R., Martinuzzo M.E., de Larranga G.F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005; 14: 129-36.</p><p>Zhang M., Tracey K.J. Tumor necrosis factor. The cytokine handbook. 3rd ed. A.W. Thompson (ed.). New York: Academic Press, 1998; 515-48.</p><p>Chia S., Qadan M., Newton R. et al. Intra-arterial tumor necrosis factor-а impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vascul Biol 2003; 23: 659-65.</p><p>Bertolini D.R., Nedwin G.E., Bingman T.S. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986; 319: 516-8.</p><p>Svenungsson E., Gunnarsson I., Fei G.Z. et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthr Rheum 2003; 48: 2533-40.</p><p>Warne J.P. Tumor necrosis factor а: a key regulator of adipose tissue mass. J Endocrinol 2003; 377: 351-5.</p><p>Кричевская О.А., Клюквина Н.Г., Александрова Е.Н. и др. Фактор некроза опухоли а и его растворимые рецепторы при ревматических заболеваниях: клиническое и патогенетическое значение. Науч.-практич. ревматол. 2005; 2: 43-6.</p><p>Bertolaccini M.L., Atsumi T., Lanchbury J.C. et al. Plasma tumor necrosis factor alpha level and 238* promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001; 85: 193-4.</p><p>Бородин А.Г., Баранов А.А., Клюквина Н.Г. и др. Клинико-патогенетическое значение фактора некроза опухоли альфа при системной красной волчанке. Тер. арх. 2002; 5: 32-4.</p><p>Кричевская О.А., Клюквина Н.Г., Александрова Е.Н. и др. Клиническое значение растворимых рецепторов фактора некроза опухоли а у больных системной красной волчанкой. Клин. мед. 2004; 10: 51-5.</p><p>Ильина А.Е., Клюквина Н.Г., Александрова Е.Н. и др. Растворимые рецепторы α-фактора некроза опухолей: связь с атеросклеротическим поражением сосудов при системной красной волчанке у мужчин. Тер. арх. 2006; 6: 20-4.</p><p>Howard M., O'Garra A., Ishida H. et al. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 239-42.</p><p>Rousset F., Garcia E., Defrance T. et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-3.</p><p>Llorente L., Zou W., Levy Y. et al. Role of interleukin 10 in the B lymphocyte hyper- activity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-44.</p><p>Ishida H., Muchamuel T., Sakaguchi S. et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-10.</p><p>Capper E.R., Maskill J.K., Gordon C., Blakmore A.I. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patients subgroups of different pathology? Clin Exp Immunol 2004; 138: 348-56.</p><p>Llorente L., Richaud-Patin Y., Wijdenes J. et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421-7.</p><p>Mallat Z., Besnard S., Duriez M. et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: 17-24.</p><p>Fei G.Z., Svenungsson E., Frostegard J., Padyukov L. The A-1087 IL-10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004; 177: 409-14.</p><p>Westerweel P.E., Luyten R.K., Koomans H.A. et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthr Rheum 2007; 56: 1384-96.</p><p>Okamura H., Tsutsi H., Komatsu T. et al. Cloning of a new cytokine that induces IFN- gamma production by T cells. Nature 1995; 378: 88-91.</p><p>Micallef M.J. Ohtsuki T., Kohno K. et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26: 1647-51.</p><p>Tsutsui H., Nakanishi K., Matsui K. et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 3967-73.</p><p>Mallat Z., Corbaz A., Scoazec A. et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.</p><p>Blankenberg S., Tiret L., Bickel C. et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.</p><p>Blankenberg S., Luc G., Ducimetiere P. et al. Interleukin-18 and the risk for coronary heart disease in European men. The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-9.</p><p>Aso Y., Okumura K., Takebayashi K. et al. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003; 26: 2622-7.</p><p>Hung J., McQuillan B.M., Chapman C.M.L. et al. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 1268-73.</p><p>McLachlan C.S., Chua W.C., Wong P.T. et al. Homocysteine is positively associated with cytokine IL-18 plasma levels in coronary artery bypass surgery patient. Biofactors 2005; 23: 69-73.</p><p>Esposito K., Pontillo A., Ciotola M. et al. Weight loss reduces IL-18 levels in obese women. J Clin Endocrinol Metab 2002; 87: 3864-6.</p><p>Панафидина Т.А., Попкова Т.В., Алекберова З.С. и др. Интерлейкин-18 при системной красной волчанке: связь с клиническими проявлениями заболевания и атеросклеротическим поражением сосудов. Тер. арх. 2008; 5: 41-6.</p><p>Wong C.K., Li E.K., Lam C.W.K. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000; 39: 1078-81.</p><p>Andre P., Nannizzi-Alaimo L., Prasad S.K., Plillips D.R. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.</p><p>Ferro D., Pignatelli P., Loffredo L. et al. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. Arthr Rheum 2004; 50: 1693-4.</p><p>Freedman J.E. CD40-ligand assessing risk instead of damage? N Engl J Med 2003; 348: 1163-5.</p><p>Kato K., Santana-Sahagun E., Rassenti L.Z. et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947-55.</p><p>Phillips R.P. Atherosclerosis: the emerging role of inflammation and CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000; 97: 6930-2.</p><p>Schцnbeck U., Varo N., Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.</p><p>Van Kooten C., Blanchereau J. CD40- CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61: 1-77.</p><p>Schцnbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.</p><p>Schцnbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-103.</p><p>Andre P., Prasad S.K., Denis C.V. et al. CD40L stabilizes arterial thrombi by a beta-3 integrin-dependent mechanism. Nat Med 2002; 8: 247-52.</p><p>Александрова Е.Н., Новиков А.А., Насонов Е.Л. Растворимый лиганд CD40 при аутоиммунных заболеваниях и атеросклерозе. Тер. арх. 2005; 12: 91-5.</p><p>Allanore Y., Borderie D., Meune C. et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005; 64: 481-3.</p><p>Tamura N., Kobayashi S., Kato K. et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 2001; 28: 2583-90.</p><p>Scalzi V.V., Cron R.C., von Feldt J.M. Correlation of increased soluble CD40 ligand levels and coronary artery calcification in SLE patients (abstract). Arthr Rheum 2002; 45(Suppl. 9): 55.</p><p>Vakkalanka R.K., Woo C., Kiron K.A. et al. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthr Rheum 1999; 42: 871-81.</p><p>Попкова Т.В., Панафидина Т.А., Александрова Е.Н. и др. Растворимый CD40-лиганд при системной красной волчанке: связь с атеросклеротическим поражением сосудов. Тер. арх. 2008; 5: 37-41.</p><p>Александрова Е.Н., Новиков А.А., Попкова Т.В. и др. Растворимый лиганд CD40 при системной красной волчанке и антифосфолипидном синдроме. Тер. арх. 2006; 6: 35-9.</p><p>Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 523-6.</p><p>Насонов Е.Л., Самсонов М.Ю., Тилз Г., Фукс Д. Неоптерин: новый иммунологический маркер аутоиммунных ревматических заболеваний. Клин. мед. 2000; 8: 43-6.</p><p>Фукс Д., Самсонов М.Ю., Насонов Е.Л., Беленков Ю.Н. Клиническое значение неоптерина при заболеваниях человека. Тер. арх. 1993; 5: 80-7.</p><p>Mahmoud R.A., El-Gendi H.I., Ahmed H.H. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 2005; 38: 134-41.</p><p>Rudzite V., Jurica E., Schroecksnadel K. et al. Usefulness of neopterine, C-reactive protein, homocystein, piridoxol-5phosphatase, and phospholipid determination in coronary artery disease. Pteridines 2005; 16: 15-21.</p></div><br />


Для цитирования:


Александрова Е.Н., Новиков А.А., Решетняк Т.М., Насонов Е.Л. ИММУНОЛОГИЧЕСКИЕ МАРКЕРЫ АНТИФОСФОЛИПИДНОГО СИНДРОМА. ЧАСТЬ II - МАРКЕРЫ ПОВРЕЖДЕНИЯ ЭНДОТЕЛИЯ, ВОСПАЛЕНИЯ И АКТИВАЦИИ КЛЕТОЧНОГО ИММУНИТЕТА. Научно-практическая ревматология. 2010;48(5):67-74. https://doi.org/10.14412/1995-4484-2010-733

For citation:


Aleksandrova E.N., Novikov A.A., Reshetnyak T.M., Nasonov E.L. IMMUNOLOGIChESKIE MARKERY ANTIFOSFOLIPIDNOGO SINDROMA. ChAST' II - MARKERY POVREZhDENIYa ENDOTELIYa, VOSPALENIYa I AKTIVATsII KLETOChNOGO IMMUNITETA. Rheumatology Science and Practice. 2010;48(5):67-74. (In Russ.) https://doi.org/10.14412/1995-4484-2010-733

Просмотров: 651


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)